UK starts real-time review of Moderna's COVID-19 vaccine candidate
Oct 27 (Reuters) - Moderna Inc MRNA.O said on Tuesday United Kingdom's health regulator has started a real-time review of its experimental COVID-19 vaccine candidate.
The company has begun a rolling data submission from its vaccine candidate to UK's Medicines and Healthcare products Regulatory Agency (MHRD) for it to start its independent assessment of evidence as and when it becomes available.
Such a process allows for a reduced time to approve a treatment, while maintaining the same standards of safety and effectiveness.
Moderna said earlier this month it was going to apply for real-time reviews of its experimental COVID-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc PFE.N and AstraZeneca AZN.L.
Canada's health ministry is also in the process of reviewing Moderna's COVID-19 vaccine candidate in real time, the company said earlier this month. (https://reut.rs/3kztkvr)
(Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.